Stockreport

Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95 [Yahoo! Finance]

Context Therapeutics Inc.  (CNTX) 
PDF PHILADELPHIA, April 09, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engager [Read more]